Wall Street investors pour money into developing new psychedelic treatments for mental illnesses; extreme temperature fluctuations around the country can pose health risks; Moderna and Merck's combination skin cancer treatment receives breakthrough designation from the FDA.
Researchers looked at trends in insulin usage and expenditure among insured and uninsured populations with diabetes, accounting for how the expansion of Medicaid under the Affordable Care Act may have affected these trends.
Utilizing real-world evidence that applies to the specific care needs of certain patient populations can promote timely decision-making among payers and providers on the use of effective cancer therapies available on the market, said panelists at the 2022 Patient-Centered Oncology Care® (PCOC) meeting.
Tochi M. Okwuosa, DO, Rush University Medical Center, discusses ways in which cancer treatments can adversely affect heart health outcomes for patients under the care of oncologists.
Results from a phase 2 study suggests that the oncolytic virus talimogene laherparepvec has potential to improve therapy responses for patients undergoing neoadjuvant chemotherapy for triple-negative breast cancer (TNBC).
School nurses reported improved knowledge and confidence in the care of students with seizures after undergoing the Project ECHO (Extension for Community Healthcare Outcomes) telementoring program for epilepsy.
A review found that visual impairment is common in older adults with dementia and associated with negative effects.
Merck’s COVID-19 pill has been shown to not be successful against household infection risk; the government plans to allow states to use Medicaid funds for prison drug treatment and other services; Ozempic, used to treat type 2 diabetes, is in short supply because it’s being sought for weight loss.
Investigators compared these outcomes due to limited research in the space, with previous surveys suggesting care disparities.
Researchers found that the anticoagulant effects of apixaban, betrixaban, edoxaban, and rivaroxaban were partially neutralized at an andexanet alfa dose of 50 mcg/mL and were completely neutralized at 100 mcg/mL.
A single session of self-managed virtual reality (VR) exercise may help reduce endometriosis pain, a study suggests.
On this episode of Managed Care Cast, we speak with Simon F. Haeder, PhD, MPA, professor of public health at the Texas A&M University School of Public Health. He and his co-investigators looked at the accuracy of directories of psychiatrists and nonphysician mental health providers for all plans regulated by the California Department of Managed Health Care in 2018 and 2019.
At Patient-Centered Oncology Care®, Debra Patt, MD, PhD, MBA, of Texas Oncology, discussed managed care considerations that arise from the groundbreaking DESTINY-Breast04 study presented earlier this year.
Imaging and clinical characteristics reach high diagnostic efficacy when they are used to identify frequent acute exacerbations in patients with chronic obstructive pulmonary disease (COPD).
A new study has found that adults who were vaccine hesitant were more likely to show a positive change in opinion when presented with an interactive risk ratio simulation.
Guideline-directed cancer care—with help from a clinical support tool—can close disparities while reducing costs more efficiently than other means, such as prior authorization.
A fifth person has been cured of HIV following a stem cell transplant for cancer; a new study examining a treatment of spinal cord stimulation after stroke had favorable results; some food companies enraged by proposed FDA healthy food guidelines.
Joneigh Khaldun, MD, MPH, FACEP, vice president and chief health equity officer for CVS Health, speaks on the goals of the Community Equity Alliance in improving health care disparities, particularly for cardiovascular health and mental health outcomes, within underserved communities.
There are 2 ranibizumab biosimilars approved in the United States, and with more ranibizumab and the first aflibercept biosimilars on the horizon, gaps in knowledge among retinal physicians should be addressed.
Patients with myelofibrosis (MF) who achieved a spleen response while taking ruxolitinib and lost it had survival outcomes similar to patients who did not respond, according to results from a real-world study.
A different type of test may improve diagnosis for some patients with myasthenia gravis (MG).
Senators concerned over health care worker shortages; Medicaid beneficiaries left unaware of renewal deadline; Ohio to open health clinic after toxic train derailment.
The authors identified 2 subgroups with non–small cell lung cancer (NSCLC) who had different responses to common cancer therapies.
An increased risk of hospitalization for more than 6 days due to community-acquired infections was associated with male sex and admittance to the Pulmonology or Surgery department, with risk shown to differ according to pathogen.
The second half of 2022 brought the first gene therapies for hemophilia to the market in both the United States and abroad.
Relugolix was frequently used in combination with other medications for prostate cancer in patients both new to androgen-deprivation therapy and continuing androgen-deprivation therapy in a real-world study.
We’ve found through health equity initiatives that the search for the right telehealth modality is never ending, explained Oncology Consultants of Houston’s Susan Sabo-Wagner, MSN, RN, OCN, executive director of clinical strategy.
Investigators note that although the overall cost for implementing next-generation sequencing (NGS) testing would be more than implementing current polymerase chain reaction (PCR)–based testing, the assay may be more cost effective overall because it screens for multiple conditions.
The results of the futility analysis also suggest the therapy leads to significant clinical benefits.
Despite coming at a high cost, an analysis found that in some cases, chimeric antigen receptor T-cell therapy may be cost-effective compared with the standard of care in the second line or later for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
